GlassScriptPhysician profile
Jacque T Labarre
NPI 1639154693
$1,296.39
in general payments reported to CMS, 2019-2025
22 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $140 · 2021: $243 · 2022: $73.66 · 2023: $261 · 2024: $110 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.37 | 2019-2024 | |
| Avion Pharmaceuticals | $101.76 | 2019-2021 | |
| Evofem Biosciences, INC. | $100.37 | 2020-2025 | Phexxi, Solosec, Phexx |
| Pfizer INC. | $74.05 | 2019-2024 | |
| Sage Therapeutics, LLC | $67.20 | 2025 | Zurzuvae |
| Millicent US INC | $62.80 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Hologic Sales and Service, LLC | $55.30 | 2019-2025 | Myosure Tissue Removal Device |
| Exeltis, USA INC. | $51.31 | 2023-2025 | Slynd |
| Astellas Pharma US INC | $42.99 | 2023-2025 | Veozah |
| Novo Nordisk INC | $42.49 | 2023-2024 | Wegovy |
| Merck Sharp & Dohme LLC | $41.81 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.86 | 2021-2023 | |
| Organon LLC | $26.67 | 2022-2025 | Jada System |
| Coopersurgical, INC. | $25.81 | 2023 | Mara Console |
| Supernus Pharmaceuticals, INC. | $25.67 | 2025 | Qelbree |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $24.38 | 2025 | Ligasure |
| Mayne Pharma Commercial LLC | $24.28 | 2023 | |
| Dexcom, INC. | $22.81 | 2025 | Dexcom G6 Transmitter |
| Lupin INC. | $15.65 | 2020 | |
| Duchesnay USA Incorporated | $14.92 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.68 | 2019 | |
| Amgen INC. | $14.21 | 2023 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacque Labarre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.